The FDA approved weekly insulin Awiqli for children 10 and up with type 2 diabetes, while Lilly's retatrutide data adds pressure before Novo's nine-month numbers.
Recap by typeshit. Full story at ad-hoc-news.de.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
A link to the FDA's list of bulk drug substances it says may carry significant safety risks in compounding, relevant to the peptide policy fight.
The tablets would release the peptides in the colon, aimed at left-sided ulcerative colitis. Neither peptide is FDA-approved, and delivery tests so far used budesonide, not these peptides.
Loading…